You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CD14152

Showing 1 - 9 of 9
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Moderate-to-severe Atopic Dermatitis Trial (Nemolizumab, CD14152 )

Withdrawn
  • Moderate-to-severe Atopic Dermatitis
  • (no location specified)
Jan 6, 2022

Atopic Dermatitis Trial in Bulgaria, United States (Nemolizumab, CYP 450 Substrates)

Recruiting
  • Atopic Dermatitis
  • North Hollywood, California
  • +6 more
Nov 29, 2022

Prurigo Nodularis Trial in Austria, United States (Nemolizumab, Placebo)

Recruiting
  • Prurigo Nodularis
  • Irvine, California
  • +4 more
Aug 12, 2022

Moderate-to-Severe Atopic Dermatitis Trial in Worldwide (Nemolizumab)

Recruiting
  • Moderate-to-Severe Atopic Dermatitis
  • Fountain Valley, California
  • +30 more
Jul 20, 2022

Atopic Dermatitis Trial in United States (Nemolizumab)

Completed
  • Atopic Dermatitis
  • Nemolizumab
  • Fountain Valley, California
  • +9 more
Aug 19, 2021

Prurigo Nodularis Trial in Worldwide (Nemolizumab 30 mg, Placebo)

Recruiting
  • Prurigo Nodularis
  • Nemolizumab 30 mg
  • Placebo
  • Birmingham, Alabama
  • +109 more
Jun 29, 2022

Chronic Kidney Disease Associated Moderate to Severe Pruritus Trial in Worldwide (Nemolizumab, Placebo)

Recruiting
  • Chronic Kidney Disease Associated Moderate to Severe Pruritus
  • Hoover, Alabama
  • +77 more
Dec 13, 2022

Prurigo Nodularis Trial in Worldwide (CD14152 Dose A, CD14152 )

Completed
Has Results
  • Prurigo Nodularis
  • CD14152 Dose A
  • CD14152 placebo
  • Graz, Austria
  • +15 more
Feb 7, 2020

Moderate-to-Severe Atopic Dermatitis Trial in Worldwide (Placebo, Nemolizumab)

Active, not recruiting
  • Moderate-to-Severe Atopic Dermatitis
  • Little Rock, Arkansas
  • +201 more
Aug 24, 2022